Results 131 to 140 of about 9,592 (241)

Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience

, 2019
Zamir Butt, Syed Muhammad Ali Shah
openalex   +2 more sources

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects [PDF]

, 2016
Lisa Ross, Ivy Song, Niki Arya, Mike Choukour, Jian Zong, Shu‐Pang Huang, Timothy Eley, Brian Wynne, Ann M. Buchanan   +8 more
openalex   +1 more source

Comparative study between Ledipasvir based regimen and Daclatasvir based regimen as regard incidence of Hepatocellular Carcinoma after successful Therapy for patients with chronic hepatitis C virus infection [PDF]

, 2021
Mahmoud A. Osman, Ehab Hassan Nashat Allam, Christina Alfonse Anwar, Mohammed Soliman Mahmoud Allam   +3 more
openalex   +1 more source

Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study [PDF]

, 2019
Hanan Mahmoud Fayed, Ali A. Ghweil, Mona Abdelmeguid   +2 more
openalex   +1 more source

Biochemical and Demographic Factors Affecting Antiviral Treatment Failure in Hepatitis C Patients with Persistent Virologic Response Issues

Pakistan Journal of Medical Research
Background: Worldwide, Hepatitis C virus (HCV) infection is a major public health concern. Twelve weeks following treatment completion, the persistent virologic response is known as SVR.
Sundus Bukhari, Mutayyaba Majeed, Maria Liaqat, Sana Shakeel, Maria Muddassir, Faheem Hadi, Tahir Maqbool   +6 more
doaj  

Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures. [PDF]

AMB Express
Abd Elsalam MA, Kutkat O, Moatasim Y, Mostafa A, Gaballah M, Elgendy AE, Ali MA, Hadad G, Shabayek S.   +8 more
europepmc   +1 more source

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

, 2013
G.J. Dore, E. Läwitz, Christophe Hézode, Stephen D. Shafran, A. Ramji, H. Tatum, Gloria Taliani, Albert Tran, Maurizia Rossana Brunetto, S. Zaltron, Simone I. Strasser, Nina Weis, W. Ghesquiere, S. Lee, Dominique Larrey, S. Pol, H. Harley, Joseph George, Samuel Fung, Victor de Lédinghen, Peggy Hagens, David Cohen, Elizabeth Cooney, Stephanie Noviello, Eric Hughes   +24 more
openalex   +1 more source

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled,double-blinded study [PDF]

, 2020
Hossam H. Mohamed, Nagwa A. Sabri, Hossam A. Zaki, Sara M. Shaheen   +3 more
openalex   +1 more source

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. [PDF]

Ann Med Surg (Lond)
Sajjad W, Rehman UU, Inam A, Alam I, Ghafoor S, Razzaq HD, Khwajakhail T, Gillani SHMUD, Razzaq H, Qamar I, Ali R, Ullah Z.   +11 more
europepmc   +1 more source